ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
3.955
-0.065
( -1.62% )
Updated: 10:15:25

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
3.955
Bid
3.88
Ask
4.14
Volume
3,093
3.955 Day's Range 4.09
3.51 52 Week Range 20.72
Market Cap
Previous Close
4.02
Open
4.03
Last Trade
8
@
4.06
Last Trade Time
10:17:56
Financial Volume
$ 12,469
VWAP
4.0314
Average Volume (3m)
32,806
Shares Outstanding
29,609,814
Dividend Yield
-
PE Ratio
-9.11
Earnings Per Share (EPS)
-0.44
Revenue
-
Net Profit
-13.07M

About Telomir Pharmaceuticals Inc

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new tre... Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Tampa, Florida, USA
Founded
1970
Telomir Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TELO. The last closing price for Telomir Pharmaceuticals was $4.02. Over the last year, Telomir Pharmaceuticals shares have traded in a share price range of $ 3.51 to $ 20.72.

Telomir Pharmaceuticals currently has 29,609,814 shares outstanding. The market capitalization of Telomir Pharmaceuticals is $119.03 million. Telomir Pharmaceuticals has a price to earnings ratio (PE ratio) of -9.11.

TELO Latest News

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development...

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

TAMPA, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development...

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines...

New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces broadcasting of its national business show that will air as a sponsored program on Bloomberg TV on Saturday...

Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- FMW Media Works' New to The Street televised business show will feature Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ($TELO) ("Company"), a...

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging...

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Telomir’s pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase New York...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.125-3.06372549024.084.373.72271603.95203711CS
4-1.065-21.21513944225.025.28443.51369234.13429268CS
12-3.315-45.5983493817.277.43.51328065.30057242CS
26-3.045-43.5720.723.51508617.29672126CS
52-3.045-43.5720.723.51508617.29672126CS
156-3.045-43.5720.723.51508617.29672126CS
260-3.045-43.5720.723.51508617.29672126CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
 20.09
(838.79%)
91.31k
ADILAdial Pharmaceuticals Inc
$ 2.50
(135.85%)
105.21M
SLRXSalarius Pharmaceuticals Inc
$ 2.72
(76.62%)
1.6M
ATPCAgape ATP Corporation
$ 0.2271
(58.81%)
74.45M
SMFLSmart for Life Inc
$ 2.97
(54.69%)
6.84M
JAGXJaguar Health Inc
$ 1.455
(-65.93%)
7.19M
RNAZTransCode Therapeutics Inc
$ 0.2998
(-62.17%)
3.97M
MIRAMIRA Pharmaceuticals Inc
$ 3.06
(-38.92%)
14.92M
XCURExicure Inc
$ 0.3543
(-29.11%)
314.65k
PSIGPS International Group Ltd
$ 2.0884
(-22.65%)
233.87k
ADILAdial Pharmaceuticals Inc
$ 2.50
(135.85%)
105.21M
ATPCAgape ATP Corporation
$ 0.2271
(58.81%)
74.45M
WRNTWarrantee Inc
$ 0.3001
(3.13%)
60.75M
GPAKGamer Pakistan Inc
$ 0.1791
(7.83%)
44.17M
NVDANVIDIA Corporation
$ 123.63
(0.07%)
41.51M